The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of Limited Heart Monitoring During Non-anthracycline Trastuzumab-based Therapy in Breast Cancer Patients
Official Title: A Safety and Feasibility Study of Limited Cardiac Monitoring During Non-anthracycline Trastuzumab-based Therapy in Patients With HER2-positive Breast Cancer
Study ID: NCT03983382
Brief Summary: The purpose of this study is to test whether patients with breast cancer who are being treated with non-anthracycline trastuzumab therapy can safely be monitored for heart related side effects less often than usual.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only), Hartford, Connecticut, United States
Memorial Sloan Kettering Cancer Center @ BaskingRidge (Consent and follow-up only), Basking Ridge, New Jersey, United States
Memorial Sloan Kettering Monmouth (Consent and Follow up), Middletown, New Jersey, United States
Memorial Sloan Kettering Bergen (Consent and follow-up only), Montvale, New Jersey, United States
Memorial Sloan Kettering Cancer Center @ Commack (Consent and Follow up), Commack, New York, United States
Memorial Sloan Kettering Westchester (Consent and Follow-up), Harrison, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Memorial Sloan Kettering Nassau (Consent and Follow-up), Rockville Centre, New York, United States
Name: Anthony Yu, MD
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR